Treatment of adult rhabdoid renal cell carcinoma with sorafenib | Zendy

Anil Kapoor | Zendy; Robert Tutino | Zendy; Androniki Kanaroglou | Zendy; Sébastien J. Hotte | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of adult rhabdoid renal cell carcinoma with sorafenib

Author(s) -

Anil Kapoor,

Robert Tutino,

Androniki Kanaroglou,

Sébastien J. Hotte

Publication year - 2008

Publication title -

canadian urological association journal

Language(s) - English

Resource type - Journals

eISSN - 1920-1214

pISSN - 1911-6470

DOI - 10.5489/cuaj.983

Subject(s) - sorafenib , renal cell carcinoma , malignancy , tyrosine kinase inhibitor , medicine , clear cell renal cell carcinoma , oncology , tyrosine kinase , cancer research , sunitinib , pathology , hepatocellular carcinoma , cancer , receptor

Renal cell carcinoma (RCC) with rhabdoid features is an uncommon and highly aggressive malignancy. We report a case of adult clear-cell RCC with extensive rhabdoid features treated with the tyrosine kinase inhibitor sorafenib. A review of the literature summarizes important aspects of this malignancy. We discuss clinical and histological findings as well as the patient’s response to sorafenib therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research